Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Phase II Trial of Bexarotene for Advanced Differentiated Thyroid Cancer.

× No keyword cloud information.

4 in total

1. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

Authors: M Duvic; A G Martin; Y Kim; E Olsen; G S Wood; C A Crowley; R C Yocum
Journal: Arch Dermatol Date: 2001-05

2. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids.

Authors: Bryan R Haugen; Lori Lee Larson; Umarani Pugazhenthi; William R Hays; Joshua P Klopper; Cynthia A Kramer; Vibha Sharma
Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958

3. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.

Authors: Ying Y Liu; Marcel P Stokkel; Alberto M Pereira; Eleonora P Corssmit; Hans A Morreau; Johannes A Romijn; Johannes W A Smit
Journal: Eur J Endocrinol Date: 2006-04 Impact factor: 6.664

4. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment.

Authors: Joshua P Klopper; William R Hays; Vibha Sharma; Margaret A Baumbusch; Jerome M Hershman; Bryan R Haugen
Journal: Mol Cancer Ther Date: 2004-08 Impact factor: 6.261

4 in total

1 in total

Review 1. Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy.

Authors: Viera Dobrotkova; Petr Chlapek; Pavel Mazanek; Jaroslav Sterba; Renata Veselska
Journal: BMC Cancer Date: 2018-11-01 Impact factor: 4.430

1 in total